BIO-TECHNE Corp (TECH)
$72.36-$0.11 (-0.15%) Today
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 11 | 302,815 | |
| Option exercise | 34 | 292,286 | |
| Tax withholding / forfeiture | 10 | 100,880 | |
| Derivative transaction | 10 | 159,872 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
64 Form 4 filings on record, the earliest from Oct 28, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Roeland Nusse - Director | Grant or award | Common Stock | 1,462 | $0.00 | - | |
| Roeland Nusse - Director | Grant or award | Stock Options (Right to Buy) | 3,511 | $0.00 | - | |
 Robert V. Baumgartner - Director | Grant or award | Common Stock | 1,462 | $0.00 | - | |
| Robert V. Baumgartner - Director | Grant or award | Stock Options (Right to Buy) | 3,511 | $0.00 | - | |
| Joseph D. Keegan - Director | Grant or award | Common Stock | 1,462 | $0.00 | - | |
| Joseph D. Keegan - Director | Grant or award | Stock Options (Right to Buy) | 3,511 | $0.00 | - | |
| Julie L. Bushman - Director | Grant or award | Common Stock | 1,462 | $0.00 | - | |
| Julie L. Bushman - Director | Grant or award | Stock Options (Right to Buy) | 3,511 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 64 TECH filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
BIO-TECHNE Corp (TECH) had 16 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for TECH runs to 64 Form 4 filings, the earliest from 2024-10-28. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TECH were filed in the last 90 days.
No insider sales of TECH were filed in the last 90 days. 4 sales are on record for this company.
This page tracks TECH Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TECH to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
